Phase Ia study of a hypoxic cell sensitizer doranidazole (PR-350) in combination with conventional radiotherapy-Reference-Cited by-同舟云学术

Phase Ia study of a hypoxic cell sensitizer doranidazole (PR-350) in combination with conventional radiotherapy

Published:2001-01 Issue:1 Volume:12 Page:1-6
ISSN:0959-4973
Container-title:Anti-Cancer Drugs
language:en
Short-container-title:Anti-Cancer Drugs

Author:

Nemoto Kenji,Shibamoto Yuta,Ohmagari Jun-ichi,Baba Yuji,Ebe Kazuyu,Ariga Hisanori,Takai Yoshihiro,Ouchi Atsushi,Sasai Keisuke,Shinozaki Misao,Tsujitani Michihiko,Sakaguchi Masakazu,Yamada Shogo,Sakamoto Kiyohiko

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology (medical),Pharmacology,Oncology

Reference23 articles.

1. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck

2. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome

3. Intratumoral pO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix

4. Influence of the hypoxic subvolume on the survival of patients with head and neck cancer

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radioimmunotherapy with 177Lu-DOTA-Rituximab: Final Results of a Phase I/II Study in 31 Patients with Relapsing Follicular, Mantle Cell, and Other Indolent B-Cell Lymphomas;Journal of Nuclear Medicine;2013-04-09

2. Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia;Future Oncology;2013-01

3. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia;Expert Review of Anticancer Therapy;2010-10

4. Enhanced local tumour control after single or fractionated radiation treatment using the hypoxic cell radiosensitizer doranidazole;Radiotherapy and Oncology;2008-06

5. Regulation of Cell Survival and Death Signals Induced by Oxidative Stress;Journal of Clinical Biochemistry and Nutrition;2008